Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7DWLY)

• Drug Name: GLR2007 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Glioblastoma of brain	2A00.00	Phase 1/2	[1]
Non-small-cell lung cancer	2C25.Y	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM7DWLY

Molecule-Related Drug Atlas

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[3]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[4]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[5]
Ribociclib succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[6]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[7]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[8]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[10]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[11]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[12]

Drug(s) Targeting Cyclin-dependent kinase 6 (CDK6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[3]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[4]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[5]
Ribociclib succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[6]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[7]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[8]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[12]
FCN-437	DMQ8VUW	Breast cancer	2C60-2C65	Phase 1/2	[13]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
G1T28-1	DML028U	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 4 (CDK4)	TT0PG8F	CDK4_HUMAN	Inhibitor	[2]
Cyclin-dependent kinase 6 (CDK6)	TTO0FDJ	CDK6_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04444427) Evaluation of GLR2007 for Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
• [3] Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [8] Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
• [9] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [10] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [11] Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
• [14] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.